Rosiglitazone
Ischemia Reperfusion Injury
Radboud University Medical CenterSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Ischemia Reperfusion Injury cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril Beijing Tiantan Hospital | Phase 2 | CCC |
Pc-Sod Beijing Tide Pharmaceutical Co., Ltd | Phase 2 | NR |
N-Acetyl-L-Cysteine Istituto Clinico Humanitas | Phase 2 | NR |
Same molecule, other indications
Rosiglitazone is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →